Result
-€52,946 -€52,946
From profit to loss in 2025, after a profit of €123,113 in 2024.
EUROPABIO
Lifetime
19 annual accounts with figures on one time axispeak €2.9m (2020)
€1.2m▼ 6.5%
lowest -€52,946 (2025)
-€52,946▼ €176,060
peak €3.9m (2024)
€3.8m▼ 1.4%
€129,904▼ 23.5%
peak 17.1 FTE (2015)
10.4 FTE▼ 15.4%
Board76 names since 2018all names
24 directorsLECHANTEUR Marcel and 23 others
Documentsfilings and deeds
28-08-202628 days late
2025financial year
Loss of €52,946Staff from 12.3 FTE to 10.4 FTE5 directors appointed, 2 resignations, 6 reappointments 24-09Debts from €169,864 to €129,904
Key points
from the 2025 annual accountsStaff
12 employees on 31-12-2025
In 2025, 8 people joined and 7 left.
Filings
19 annual accounts since 2006
Six of the last ten came late. The 2019 accounts came latest: 38 days after the end of the period.
At the same address
22 companies
Board
6 joined · 6 left
Board changed. Latest change 31-07-2026 · 26 in office.
Position in the sector
-€52,946
Lower net result than 85% of companies in advertising and market research. Sector median €33,699 · 847 companies.
Checked score
94
Excellent
Financially stronger than 56% of small companies in advertising and market research (NACE 73)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 722 companies (NACE 73, small).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026lowest value
03-2026: < 0.1%● unchanged vs 02-2026lowest value
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Legal form: int'l non-profit association
Liquidity: current ratio 30.78, cash €1.6m
Equity €3.8m (93.9% of total assets)
Founded in 2002
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 73, small). It does better than 87% of them on solvency, 97% on liquidity, 10% on profitability and 28% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 8,617 companies had the same profile as EUROPABIO has now. Each dot stands for 22 companies, two years later.
94.2%
were still trading
5.2%
stopped another way
0.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of EUROPABIO itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 8,617 companies, not a prediction for EUROPABIO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €350,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 30.78, above the usual 1.5. Short-term debt is 3.2% and cash 38.3% of total assets. 6.1% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · A punctual record breaks
This company filed 3 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days late. Weigh it accordingly: of the companies that move to filing 1 to 90 days late, 1.41% are now bankrupt, dissolved or in another special legal status, below the 1.66% of all filers. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
28 days late
2024
14 days early
2023
21 days early
2022
32 days early
2020
11 days early
2019
38 days late
2018
29 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 2 days after the deadline. In the sector (NACE 73), the median for financial year 2024 was 6 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 17 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
New chair
MORRISSEY, Michael appointed, Markus STÄMPFLI resigned · General meeting of 13-10-2026 · Gazette deed
6 directors appointed, 8 resignations, 11 reappointments
Resignations: Boris AZAÏS, Stephen BATES, Philippe GHYSSELS, Peter Steen MORTENSEN, Wojciech NOWAK, Colin O'DONNELL and 2 others · Appointments: Frédéric DRUCK, Maciej GAJEWSKI, Lauren KJELDSEN, Christopher MOLLOY, Michael MORRISSEY and Hugh PULLEN (vice-chair) · Reappointments: AROCENA VELEZ, lon; BOLS, Thomas; GENT, Ricardo; HEINRICH, Peter; LECHANTEUR, Marcel; LLOYD-WATKINS, Matthew and 5 others · General meeting of 18-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0477520310
5 directors appointed, 2 resignations, 6 reappointments
Resignations: Sarah REISINGER BELNAP and Stefaan FIERS · Appointments: COLOMBO, Giovanni; GHYSSELS, Philippe; Jessica MARTINSSON (vice-chair); Markus STÄMPFLI (chair) and AROCENA VELEZ, Ion (treasurer) · Reappointments: BATES, Stephen; BRAVO ANGEL, Ana Maria; CONTI, Sabrina; SCHICK, UTE; MORTENSEN, Peter Steen and VAN HOOLAND, Tineke · General meeting of 26-06-2025 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| EUROPABIO Brussels | €4.1m | €1.2m | 93.9% | 10.4 |
| COMITE EUROPEEN DE COORDINATION DES INDUSTRIES RADIOLOGIQUES ELECTROMEDICALES ET D'INFORMATIQUE DE SANTE Brussels | €3.3m | €0.7m | 19.4% | 7 |
| EXPEDIA Brussels | €2.2m | €1.6m | 72.5% | 9.5 |
| Tronox Belgium Brussels | €3.5m | €0.9m | 77.4% | 4.5 |
| STAR LEISURE GROUP Brussels | €2.4m | €1.6m | 27.6% | 13.4 |
| Belle Vita Dilbeek | €7.7m | €1.1m | 89.2% | 10.3 |
| OPEN REAL ESTATE INFORMATION SERVICES Ghent | €3.6m | €1.7m | 20.8% | 18.5 |
These companies have the same main activity as EUROPABIO: market research and public opinion polling (NACE 73200). They are comparable in size and age: total assets between €2.2m and €7.7m, founded between 1995 and 2004.
Official details
Source: KBO- Status
- Active since 17-02-2002Normal situation
- Registered office
- 23 active companies are registered at this addressSource: KBO register, as of 9 November 2026.
- Activity
- Market research and public opinion pollingNACE 73200and 1 other
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2024
- Establishment unit
- 2.229.206.1911000 Brussels, since 17-02-2002
- Financial year end
- 31 December
- Peppol
- Reachable since 08-10-2025
Annual accounts 2025
- ≈ €2.0mestimated
- €4.1m▼ 2.2%
- Employeeson 31-12-2025
- 12▲ 9.1%
- Filing
- Filed on 28-08-2026
Insights on EUROPABIO
EUROPABIO has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.8m and a net result of -€52,946.
Equity grew by about 9.1% per year on average since 2018. In 2025 it fell by 1.4%. Its solvency ranks better than 92% of 846 sector peers (NACE 73, financial year 2025).
The computed 12-month bankruptcy probability is below 0.1% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about EUROPABIO
- What is the company number of EUROPABIO?
- The company number of EUROPABIO is 0477.520.310. The VAT number is the same number with BE in front: BE 0477.520.310.
- Where is EUROPABIO based?
- The registered office is at Kunstlaan 53, 1000 Brussels.Company details
- What does EUROPABIO do?
- According to the KBO register, the main activity is market research and public opinion polling (NACE 73200).
- What is the legal form of EUROPABIO?
- EUROPABIO is an international non-profit association (IVZW).
- When was EUROPABIO founded?
- EUROPABIO was founded on 17-02-2002.
- Is EUROPABIO still active?
- Yes, EUROPABIO is an active enterprise in the KBO register.
- How many employees does EUROPABIO have?
- EUROPABIO had an average of 10.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does EUROPABIO fall under?
- In its 2024 annual accounts, EUROPABIO states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of EUROPABIO?
- The turnover in financial year 2025 is ≈ €2.0m. This figure is estimated from the gross margin of €1.2m and 1,585 comparable companies of the same size. It probably lies between €1.4m and €3.3m. It is a rough estimate.
- Is EUROPABIO profitable?
- In financial year 2025, EUROPABIO made a loss of €52,946.
- Where can I find the annual accounts of EUROPABIO?
- EUROPABIO filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EUROPABIO due?
- EUROPABIO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.